USPTO serial 85667470
ARIAD
Reviewed by CopyMark Law Group
Status 606
- Filing date
- Status date
- Registration date
- —
- Examiner
- PARKER, JUSTINE D
- Law office
- INTENT TO USE SECTION
What this means
This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.
Need help with ARIAD?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
John P. Rynkiewicz
JOHN P. RYNKIEWICZ KAYE SCHOLER LLP901 15TH ST NW STE 700WASHINGTON, DC 20005UNITED STATESGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 001 | Diagnostic reagents, preparations and substances for medical laboratory use for detecting cancer; Diagnostic preparations for detecting genetic aberrations for scientific use; reagents, preparations and substances for the preparation or manufacture of pharmaceutical preparations for use in oncology, cardiovascular diseases including stroke, ocular disorders, central nervous system diseases and disorders including Alzheimer's and Parkinson's diseases, inflammation and inflammatory diseases, respiratory and infectious diseases, auto-immune diseases, organ transplant rejection and metabolic disorders; diagnostic kits for detecting genetic predispositions comprising diagnostic reagents, preparations and substances for scientific or medical laboratory purposes; chemical and diagnostic reagents, preparations and substances for scientific purposes | ACTIVE | — |
| 005 | Diagnostic reagents, preparations and substances for medical use for detecting cancer; Diagnostic preparations detecting genetic aberrations for medical use; Pharmaceutical preparations for use in oncology; pharmaceutical preparations for the treatment and prevention of cancer, cardiovascular diseases including stroke, ocular disorders, central nervous system diseases and disorders including Alzheimer's and Parkinson's diseases, inflammation and inflammatory diseases, respiratory and infectious diseases, auto-immune diseases, organ transplant rejection and metabolic disorders; pharmaceutical preparations used in the treatment and/or prophylaxis of viral, pulmonary, genetic, renal, musculoskeletal, neurologic and gastrointestinal diseases; diagnostic kits for detecting genetic predispositions comprising diagnostic reagents, preparations and substances for medical purposes; diagnostic reagents, preparations and substances for medical purposes; Chemical preparations for medical purposes, namely, for use in oncology, for the treatment and prevention of cancer, cardiovascular diseases including stroke, ocular disorders, central nervous system diseases and disorders, Alzheimer's and Parkinson's diseases, inflammation and inflammatory diseases, respiratory and infectious diseases, auto-immune diseases, organ transplant rejection and metabolic disorders, viral, pulmonary, genetic, renal, musculoskeletal, neurologic and gastrointestinal diseases | ACTIVE | — |
| 009 | Computer software for use in electronic storage and retrieval of medical data and medical information for healthcare professionals; computer software for personalized medicine purposes, namely scientific analysis of gene sequences; laboratory devices for detecting gene sequences | ACTIVE | — |
| 010 | Medical devices, namely, stents; Medical apparatus and instruments for diagnostic use, namely, apparatus for medical diagnostic testing in the field of cancer; medical diagnostic apparatus for detecting cancer or a predisposition to cancer; coatings sold as an integral component of medical stents and other implantable medical devices; stents | ACTIVE | — |
| 039 | Electronic storage of medical data and medical information for healthcare professionals | ACTIVE | — |
| 041 | Educational classes, seminars, presentations and programs pertaining to cancer, pharmaceuticals, genetics | ACTIVE | — |
| 042 | Providing laboratory research services in the field of gene expression, namely, cancer biology; DNA analysis services; medical and scientific research in the field of pharmaceuticals, cancer treatment and diagnosis; providing medical and scientific research information in the fields of pharmaceuticals and genetics; providing medical research and scientific information in the field of cancer prevention, pharmaceuticals, screening, diagnosis and treatment | ACTIVE | — |
| 044 | Genetic testing and screening for medical purposes; medical diagnostic testing, monitoring and reporting services; medical testing for diagnostic or treatment purposes; medical testing for diagnostic or treatment purposes in the field of cancer; medical assistance services in the nature of medical information provided to medical professionals from remote locations via the Internet and global computer networks through the use of archived medical images and a data storage and retrieval system; Medical services in the field of personalized medicine; cancer screening, diagnosis and treatment; providing medical information in the field of cancer prevention, screening, diagnosis and treatment; providing information relating to diagnostic, prophylactic and therapeutic properties of pharmaceuticals in the field of cancer | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by ARIAD Pharmaceuticals, Inc.
- Other trademarks owned by ARIAD Pharmaceuticals, Inc.
- Other trademarks in Class 001
- Other trademarks in Class 005
- Other trademarks in Class 009
- Other trademarks in Class 010
- Other trademarks in Class 039
- Other trademarks in Class 041
- Other trademarks in Class 042
- Other trademarks in Class 044
- Similar marks named ARIAD
- Prosecution event MAB6 explained
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Sep 12, 2016 | MAB6 | ABANDONMENT NOTICE MAILED - NO USE STATEMENT FILED | The intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window. |
| Sep 12, 2016 | ABN6 | ABANDONMENT - NO USE STATEMENT FILED | The intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window. |
| Feb 11, 2016 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Feb 10, 2016 | EX5G | SOU EXTENSION 5 GRANTED | — |
| Feb 5, 2016 | EXT5 | SOU EXTENSION 5 FILED | — |
| Feb 5, 2016 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Aug 15, 2015 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Aug 14, 2015 | EX4G | SOU EXTENSION 4 GRANTED | — |
| Aug 6, 2015 | EXT4 | SOU EXTENSION 4 FILED | — |
| Aug 6, 2015 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Feb 20, 2015 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Feb 19, 2015 | EX3G | SOU EXTENSION 3 GRANTED | — |
| Feb 6, 2015 | EXT3 | SOU EXTENSION 3 FILED | — |
| Feb 6, 2015 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Aug 12, 2014 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Aug 11, 2014 | EX2G | SOU EXTENSION 2 GRANTED | — |
| Aug 5, 2014 | EXT2 | SOU EXTENSION 2 FILED | — |
| Aug 5, 2014 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Feb 27, 2014 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Feb 26, 2014 | EX1G | SOU EXTENSION 1 GRANTED | — |
| Feb 24, 2014 | AITU | CASE ASSIGNED TO INTENT TO USE PARALEGAL | — |
| Jan 31, 2014 | EXT1 | SOU EXTENSION 1 FILED | — |
| Jan 31, 2014 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Jan 14, 2014 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Aug 6, 2013 | NOAM | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | A Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date. |
| Jun 11, 2013 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Jun 11, 2013 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| May 22, 2013 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| May 6, 2013 | PREV | LAW OFFICE PUBLICATION REVIEW COMPLETED | — |
| May 3, 2013 | ALIE | ASSIGNED TO LIE | — |
| Apr 24, 2013 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Apr 23, 2013 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Apr 23, 2013 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Apr 23, 2013 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Oct 23, 2012 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Oct 23, 2012 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Oct 23, 2012 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Oct 22, 2012 | DOCK | ASSIGNED TO EXAMINER | — |
| Jul 11, 2012 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Jul 5, 2012 | NWAP | NEW APPLICATION ENTERED | — |